Related Experiment Video

Updated: Apr 24, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

Simona Lamba1, Mariangela Russo1, Chong Sun2

  • 1Department of Oncology, University of Torino, Str prov 142 Km 3.95, Candiolo, 10060 Torino, Italy; Candiolo Cancer Institute-FPO, IRCCS, Str prov 142 Km 3.95, Candiolo, 10060 Torino, Italy.

Cell Reports
|September 10, 2014
PubMed

Insights

Targeting RAF and MEK kinases together shows promise for treating KRAS mutant cancers. This dual blockade overcomes resistance to MEK inhibitors, leading to tumor cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • KRAS is a frequently mutated oncogene in human cancers, but effective therapies remain elusive.
  • RAS-signaling pathways are critical for the growth of KRAS-mutant tumors.

Purpose of the Study:

  • To identify therapeutic targets within the RAS-signaling pathway for KRAS mutant cancers.
  • To investigate synthetic lethal interactions with MEK inhibition in KRAS mutant tumors.

Main Methods:

  • Utilized small interfering RNA (siRNA) and short hairpin RNA (shRNA)-based screening in KRAS mutant colorectal and lung cancer cell lines.
  • Investigated the effects of MEK inhibitors and RAF kinase inhibitors on cancer cell growth and signaling pathways.

Main Results:

  • RAF1 suppression was found to be synthetic lethal with MEK inhibition.
  • MEK inhibition can lead to resistance by inducing RAS activation and sustaining MEK-ERK signaling.
  • Dual blockade of RAF and MEK kinases effectively suppressed ERK signaling and induced apoptosis in KRAS mutant cancer cells.
  • Compounds targeting RAF kinases reversed resistance to the MEK inhibitor selumetinib.

Conclusions:

  • Combined RAF and MEK inhibition strategies are relevant for treating KRAS mutant tumors.
  • Developing combinatorial regimens targeting the RAF-MEK pathway offers a promising therapeutic approach for KRAS-driven cancers.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K